6505--Alendronate Tablets

The Department of Veterans Affairs National Acquisition Center is soliciting proposals for the supply of Alendronate Tablets in four distinct line items: 35mg in both 4-count and 12-count packages, and 70mg in both 4-count and 12-count packages. This procurement seeks to establish a supply source to serve the VA, Federal Health Care Center, State Veterans Homes, Indian Health Service, and Bureau of Prisons. Offerors must submit pricing for all line items across a base year and four one-year option periods, with a mandatory 0.5% Cost Recovery Fee included in all proposals. The solicitation utilizes a Standard Form 1449 for Commercial Products and Commercial Services, indicating evaluation will focus on pricing competitiveness and the ability to meet supply requirements through established pharmaceutical distribution channels. Proposals are due by November 13, 2025, at 2:30 PM Central Time, with an anticipated contract effective date of October 28, 2025, and one aggregate award is planned for this procurement.

This is an unrestricted procurement with no set-aside designation, though small business size standards of 1,300 employees apply under NAICS code 325412. McKesson Corporation is identified as the current prime vendor through the Pharmaceutical Prime Vendor programs, which will serve as the distribution mechanism for the awarded contract. The solicitation encompasses estimated annual usage across multiple federal and state healthcare entities, though specific award values or quantity projections are not disclosed in the notice. Distribution will occur through established Pharmaceutical Prime Vendor programs, ensuring efficient supply chain management across the designated healthcare facilities. Performance is expected to be coordinated through McKesson's existing infrastructure and the VA's pharmaceutical supply network.